Sanofi ADR

SNY

NASDAQ. Currency in USD

45.87 +0.52 ( +1.15% )

Real time prices: December 01

Market Cap.
116.28B
Beta (5Y monthly)
0.46
Price/Earnings
1.02
EPS (TTM)
43.98
Forward Dividend
1.75 (3.82%)
Ex-Dividend Date
May 27, 2022
Volume
1.99M
1y Target Est.
63.10
Day's Range
45.62
-
46.02
52 Week's Range
36.91
-
58.10

Historical Summary

Performance
EPS growth
Share Buybacks

About Sanofi ADR

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.sanofi.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
2.50B
Employees
95442
Address
54, Rue La BoEtie, Paris, France, 75008
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Latest news

The S&P 500 is on the cusp of breaking through a level that might spell the end of the bear market
The S&P 500 is on the cusp of breaking through a level that might spell the end of the bear market

Still, new 52-week highs made by individual stocks is low, putting on hold a 'buy'...
By MarketWatch - 12 hours ago

Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants
Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants

Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking...
By Zacks Investment Research - 1 day ago

Why Horizon Therapeutics Stock Is Skyrocketing Today
Why Horizon Therapeutics Stock Is Skyrocketing Today

Three big drugmakers could be interested in acquiring Horizon.
By The Motley Fool - 1 day ago

Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?

Tech layoffs are in the news, but life sciences companies seem to be doing better.
By The Motley Fool - 1 day ago

Regeneron (REGN) Outperforms YTD: What's in Store for 2023?
Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

Regeneron (REGN) has had a good run in 2022 so far and the momentum should...
By Zacks Investment Research - 6 days ago

Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer
Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the...
By Zacks Investment Research - 1 week ago

Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval
Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval

Sanofi's (SNY) Enjaymo gets approval to treat hemolytic anemia in adult patients with cold agglutinin...
By Zacks Investment Research - 1 week ago

Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset
Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset

Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield...
By Zacks Investment Research - 1 week ago